approximately 80% of the nearly 70,000 AYA patients diagnosed annually in the United States are seen and/or cared for in the community, understanding and implementing AYA care delivery in nonacademic settings is important. Recent updates to the NCCN Clinical
Search Results
Howland E. Crosswell, Kaitlin N. Bomar, Nicole Vickery, Kristina Stoeppler-Biege, Terra D. Spann, and Robert D. Siegel
Shivan J. Mehta, Sanjay Palat, Catherine Reitz, Evelyn Okorie, Caitlin McDonald, Pamela A. Shaw, Karen Glanz, and David A Asch
Background : Effective prevention and screening exists for colorectal cancer (CRC) but is underutilized, particularly in community health settings. Colonoscopy and fecal immunochemical testing (FIT) are both considered top-tier tests according
Dewilka Simons, Yolaine Jeune-Smith, Bruce Feinberg, Stephanie Fortier, and Ajeet Gajra
surveyed community hematologists/oncologists (cH/O) on their perceptions of the OlympiA trial data and the potential impact on their BRCA 1/2 testing habits in patients with early-stage BC. Methods : Between June and October 2021, practicing U.S. cH/O were
Rie Tamagawa, Shannon Groff, Jennifer Anderson, Sarah Champ, Andrea Deiure, Jennifer Looyis, Peter Faris, and Linda Watson
differed. In the smaller regional and community sites, cancer patient navigators (CPNs) were available for complex distress management. In the larger tertiary cancer centers where the CPN role is not part of the care model, psychologists and social workers
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
strengths. Data were used from a large community-based population of patients with cancer; therefore, the findings may better reflect FN risks in the real-world setting. The comprehensive clinical databases at KPSC allowed for detailed characterizations of
Jonas M Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan, and Ivy Altomare
documentation of NCCN Guideline concordant and NCCN preferred treatment regimens. We assessed patterns of concordant, preferred and non-preferred treatment regimen ordering at one large multi-site community practice. Methods : We reviewed all treatment orders
Kaustav Chatterjee, Edward Drea, Robert Smith, Mei Xue, Hunter Lambert, Jeffrey Scott, Sorena Nadaf, Simon Blanc, Prateesh Varughese, and John Verniero
following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code
Rachel J Meadows, Anna Muraveva, Christina Bijou, Kate Shane-Carson, Coralia Balasca, Celia E Wills, Lisa D Yee, Electra D Paskett, and Tasleem J Padamsee
, community-based sample. Methods : This study uses data (collected Oct 2018–Aug 2019) from a survey that included measures of risk-management behavior, potential correlates, and information necessary to determine lifetime BC risk. Eligible participants were
Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang
study aimed to assess the prevalence of HAEs and associated health care resource utilization among patients receiving chemotherapy for ES-SCLC in the community oncology setting. Methods : Adult patients with ES-SCLC included in the Integra Connect
Sydney Beache, Aimee James, Graham Colditz, and Courtney Harriss
Background : While lung cancer is a leading cause of death in the U.S., annual screening rates with low-dose Computed Tomography (LDCT) among eligible candidates remain low at 12.7%. The WUSTL research group began a community intervention to
